Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide and Muscle Cells: New Study

A six-donor cell study found no direct muscle atrophy signal from semaglutide, but it cannot settle what happens in people over time.

Why we wrote this. A new cell study offers a useful boundary on muscle-loss claims, but its small in vitro design needs careful framing.

In this article (4 sections)
  1. What the researchers tested
  2. What the study found
  3. What this means for the muscle-loss debate
  4. What we do not know

A 2026 laboratory study found that direct exposure to semaglutide did not make primary human muscle cells thinner or disrupt their differentiation. That is useful evidence against a simple direct toxicity explanation for lean mass loss during weight reduction. It is not proof that semaglutide preserves muscle in patients. The experiment used cells from six older donors, mostly short exposure windows, and no intact human bodies[1].

What the researchers tested

Researchers isolated muscle precursor cells from older adults undergoing elective hip or knee replacement for osteoarthritis. The donors had a mean age of 73 years and a mean body mass index of 32.48. None was receiving an incretin analogue or a DPP-4 inhibitor when tissue was collected. The team grew the cells into myotubes, which are fused muscle cells used as a laboratory model of skeletal muscle[1].

Differentiated myotubes from six donors were exposed to 10 nanomolar semaglutide or 5.02 micromolar native GIP. The main treatment period was 24 hours, with four-hour gene-expression tests and an eight-day differentiation experiment. The GIP concentration was deliberately far above normal post-meal blood concentrations because no established skeletal-muscle dosing model existed. The authors also noted that the free semaglutide exposure in the culture medium may have exceeded the free fraction found in blood at the same total concentration[1].

The assays covered genes linked to muscle breakdown and inflammation, 1,034 secreted proteins, energy production, glucose uptake, lactate release, myotube thickness, and differentiation. This broad set of laboratory measures helps test for a direct cell effect, but it does not reproduce appetite change, calorie restriction, activity, hormones, or mechanical loading in a living person[1].

What the study found

Neither semaglutide nor GIP changed the measured atrophy-related genes. After correction for testing many proteins, neither treatment significantly changed the secreted-protein panel. Semaglutide also did not reduce myotube thickness or impair differentiation. Native GIP increased myotube thickness after eight days, although that result belongs to this cell model and should not be read as a treatment effect in people[1].

One metabolic finding did move. Semaglutide reduced glycolytic ATP production and total ATP production, alongside lower lactate release. Glycolysis is the process cells use to extract energy from glucose without relying entirely on mitochondria. Mitochondrial measures were unchanged. The authors described the glycolytic shift as modest and not evidence of meaningful muscle impairment[2].

Receptor results were mixed. GIP receptor messenger RNA was detected in all six donors. GLP-1 receptor messenger RNA was not detected, yet a fluorescent probe found a low-level surface signal in 51% to 66% of precursor cells from three donors. Those probe tests used myoblasts, while the functional experiments used differentiated myotubes. Cultures were not purified by cell sorting, so non-muscle cells may have contributed to the signal[1].

What this means for the muscle-loss debate

The result makes one explanation less likely under the tested conditions: semaglutide did not directly switch on a strong atrophy program in isolated human myotubes. The authors say their findings are consistent with an indirect mechanism for lean mass loss during incretin treatment. Reduced calorie intake and reduced mechanical loading are plausible contributors, but this experiment did not test either mechanism in patients[2].

The paper should not be stretched to tirzepatide. It used native GIP, not a long-acting GIP receptor agonist or a dual GIP and GLP-1 receptor agonist. Engineered molecules may signal differently. Readers comparing products should also separate a change in lean mass measured during weight loss from proven loss of strength or function. This cell study measured neither clinical outcome[1].

What we do not know

Six donors provide a narrow biological sample. They were older adults with obesity and end-stage osteoarthritis, so the cultures may not represent younger or healthier muscle. Most exposures lasted 24 hours, not months or years. The study may also have missed small effects, especially across more than 1,000 secreted proteins. It cannot rule out indirect muscle changes caused by nutrition, activity, illness, or the wider hormonal environment[1].

There is also a difference between a null result and proof of no effect. Several assays found no statistically significant change, but a small experiment has limited power to detect subtle or donor-specific responses. The researchers selected endpoints that reflect known muscle pathways, yet no panel captures every possible route to altered tissue mass. A living muscle also receives blood flow, nerve signals, amino acids, and repeated mechanical load. Removing those inputs makes the model useful for isolating a direct drug effect, while narrowing what the result can answer. Longer studies that connect body composition with strength, physical function, food intake, and activity are still needed to judge clinical muscle risk[1].

The practical takeaway is modest. This paper does not support a major direct atrophy effect from semaglutide in primary human myotubes, but clinical decisions still require patient-level evidence and individual medical assessment. Semaglutide remains a prescription medicine. Its legal and approval context varies by market, which we track in the regulation library. Anyone concerned about rapid weight loss, weakness, or loss of function should discuss those symptoms with a qualified clinician rather than treating a cell experiment as personal reassurance.

Frequently asked

Did the study prove semaglutide does not cause muscle loss?

No. It found no major direct atrophy or differentiation effect in isolated human muscle cells under the tested conditions. It did not measure muscle mass, strength, diet, or activity in patients.

How many people were included in the study?

The main cell experiments used muscle cells from six older donors. This was an in vitro laboratory study, so the donors were tissue sources rather than trial participants receiving semaglutide.

What changed after semaglutide exposure?

Semaglutide modestly reduced glycolytic and total ATP production and reduced lactate release. It did not alter the measured myotube thickness, differentiation, mitochondrial parameters, or atrophy-related genes.

Can these findings be applied to tirzepatide?

Not directly. The study tested semaglutide and native GIP separately. It did not test tirzepatide or another engineered dual GIP and GLP-1 receptor agonist.

Sources

  1. [1]Ditchfield et al. (2026): GLP-1 and GIP receptor agonism in primary human myotubesTier 1 · primary↩
  2. [2]PubMed record for the 2026 GeroScience human myotube study (PMID 42980901)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars